VESTIGO
1.7.2021 09:02:13 CEST | Business Wire | Press release
Cornèr Bank Group, issuer of credit and prepaid cards to private individuals and businesses in Europe, has reached a major milestone in its digital transformation journey by completing migration of its card portfolios across all products and markets to a modern, consolidated solution. Vestigo is a European software provider in cards and account-to-account payments space, and its card management system (CMS) is the key component of the overall solution at Cornèr.
Cornèr Bank Group issues more than /2.1/ million credit and prepaid, Visa, Mastercard and Diners cards directly and through partnerships with hundreds of organizations of various sizes in a B2B2C / co-brand business model. The new solution, managed in-house on a single instance, will further improve innovation and quality of service to Cornèr Bank Group’s partners and ultimate cardholders, as well as enhance internal efficiency. Vestigo’s integrated, modular, “multi-everything” solution is fully customer centric, can manage all types of cards, as well as account-to-account payments, and allows for easy integration leveraging 200+ APIs.
This large-scale implementation and migration project was designed to minimize risk and consisted of multiple phases taking into account requirements regarding different markets, products and legacy systems.
Ing. Vittorio Cornaro, Chief Executive Officer of Cornèr Bank Group, said: “Partnering with a trusted partner like Vestigo helps us modernize and consolidate our pan-European card business, which is the key step of our strategy to transform Cornèr into an agile bank delighting our clients and partners every day with best-in-class products and services”
Simone Tettamanti, CIO at Cornèr Banca, added: This complex, large-scale project was an excellent example of two organizations working together successfully as trusted partners towards a common goal, using agile approach. This modern platform will facilitate Cornèr’s business growth and provide us with flexibility to adjust to evolving customer requirements in the future.”
Kata Kamenski, Chief Executive Officer and Co-founder of Vestigo said: “We’re incredibly proud to work with Cornèr, as this further validates Vestigo’s functionality fit, as well as delivery ability fit with sophisticated, innovative financial institutions. Vestigo continues growing strongly, driven by its differentiating capability to drive convergence across cards and account-to-account payments. Our solution is scalable and can be deployed as on-prem, cloud installation or SaaS.”
About Cornèr Bank Group
Founded in Lugano in 1952, the Cornèr Bank Group is an independent Swiss private bank group operating as a full-service bank. Lugano is Switzerland’s third-largest banking centre, after Zurich and Geneva. Active across the whole range of traditional banking services, the Cornèr Bank Group specializes in the private banking sector, as well as in the areas of lending, Visa, Mastercard and Diners Club payment cards (Cornèrcard) and online trading (Cornèrtrader) – the core businesses on which the growth of the Cornèr Bank Group is based. The Cornèr Bank Group comprises the Lugano-based parent bank Cornèr Bank Ltd., the four branches in Chiasso, Geneva, Locarno and Zurich, the branch BonusCard and the affiliates Cornèr Bank (Overseas) Limited, Cornèrcard UK Ltd., Cornèr Europe AG, Diners Club Italia S.r.l. and Dinit d.o.o.
For more information on Cornèr please visit: www.cornergroup.ch
About Vestigo
Vestigo is a founder-owned paytech, fully focused on cards (CMS) and account-to-account payments (PaymentsHub) space. Vestigo’s newest module HolisticPay is a rich payments modernization & convergence layer designed to facilitate managed cards & payments modernization. Our continuously increasing team has more than 130 employees. Vestigo’s modern, modular, customer-centric solution creates value for financial institution clients in payments, issuing and acquiring businesses. We differentiate by bringing the cards and account payments together in a fully customer centric way using modern technology. Vestigo currently supports clients in 7 European countries, with a strong growth strategy into further markets.
For more information on Vestigo please visit: www.vestigo.hr
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005043/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom